

Performance of suspected influenza case definition before and during the COVID-19 pandemic

Efrén Murillo-Zamora^a, Carlos Hernandez-Suarez^{b,*}

^a*Departamento de Epidemiología, Unidad de Medicina Familiar No. 19, Instituto Mexicano del Seguro Social, Av. Javier Mina 301, Col. Centro, CP 28000, Colima, Colima, México. Tel. +52(312) 3163770*

^b*Facultad de Ciencias, Universidad de Colima, Bernal Díaz del Castillo 340, Col. Villas San Sebastián, CP 28045 Colima, Colima, México. Tel. +52(312) 3161135*

Abstract

Background: The influenza-related burden remains high and the COVID-19 pandemic may difficult its accurate surveillance. This study aimed to evaluate the performance, before and during the COVID-19 pandemic, of the case definition of suspected influenza used in community surveillance in Mexico.

Methods: A cross-sectional analysis of a cohort study took place and cases fulfilling the suspected case criteria ($n = 20,511$), and with laboratory-conclusive evidence (quantitative real-time polymerase chain reaction) to confirm or discard influenza virus infection, were analyzed.

Results: A high sensitivity and modest specificity was documented, and this later decreased during the COVID-19 outbreak, as well as its diagnostic accuracy. However, no significant differences were observed in the Area Under the Receiver Operating Characteristics among the analyzed periods.

Conclusions: The evaluated case definition remains to be a cost-effective alternative to identify patients who may benefit from influenza-specific antiviral drugs, even during the COVID-19 global outbreak.

Keywords: Influenza; COVID-19; Pandemics; ROC Curve; Mexico.

*Corresponding author

Email address: carlosmh@mac.com (Carlos Hernandez-Suarez)

Background

The influenza-related burden remains high globally despite vaccination efforts [1]. In the northern hemisphere, seasonal cases start in October and tail off by May [2]. The case definitions of suspected influenza used in national and regional surveillance programs commonly differ from those recommended by WHO. In Mexico and according to normative standards [3], the case definition in patients aged 5 years or above includes the presence of fever (38 °C or higher), headache and cough accompanied by (at least 2): rhinorrhea, coryza, arthritis, arthralgia, myalgia, prostration, odynophagia, thoracic pain, abdominal pain, nasal congestion or diarrhea. Fever is not a cardinal symptom among elder subjects (65+ years old). Suspected cases fulfilling the criteria are classified as influenza-like illness (ILI) or severe acute respiratory infection (SARI) if systemic or distress symptoms are presented. This definition has several similarities to the proposed by the *Groupes Régionaux d'Observation de la Grippe* (GROG, the French acronym) [4], which has shown good performance in community surveillance of influenza [5].

The first registered cases of locally acquired coronavirus disease 2019 (COVID-19) in Mexico occurred in late February 2020 [6]. About three months later, over 75 thousand cases and 8 thousand deaths had been registered at national level [7]. Given that suspected cases of COVID-19 and influenza share clinical similarities [8], timely identification of these later, and which may benefit the start of neuraminidase inhibitors (NAIs) [9], may be challenging in source limited healthcare settings. We aimed to evaluate the performance of the influenza case definition before and during the COVID-19 pandemic in Mexico. We analyzed two consecutive flu seasons (2018-2020) for the benefit of a wider time framework.

Methods

We conducted a cross-sectional analysis of a nationwide retrospective cohort study. Suspected cases of influenza among individuals aged 5 years or older, and

30 registered during two consecutive seasons (2018-2020) in a normative system for the epidemiological surveillance of viral respiratory diseases (*SISVER*, the Spanish acronym), and which were later confirmed or discarded as cases of influenza virus infection, were eligible.

Quantitative real-time polymerase chain reaction (qRT-PCR; SuperScript®
35 III Platinum® One-step RT-qPCR System) analyses were performed on clinical specimens (nasopharyngeal or deep nasal swab). A detailed description of laboratory methods employed in the *Mexican Institute of Social Security (IMSS*, the Spanish acronym) network was previously published [10].

The performance of case definition of suspected influenza case was evaluated
40 in terms of sensitivity, specificity, accuracy, and positive and negative likelihood ratio (LR+/-). Age (5-9; 10-19; 20-44; 45-64 and 65 years or above) and time-stratified (according to symptoms onset: Oct. 2018-Feb. 2019; Mar. 2019-Apr. 2019; Oct. 2019-Feb. 2020; Mar. 2020-Apr. 2020) estimators were obtained. The fourth period was the pandemic one. The Area Under Receiver Operating
45 Characteristic curves (AUROCs) and 95% confidence intervals (CI) was also computed. This study was approved by the Local Ethics in Health Research Committee (601) of the *IMSS* (R-2020-601-022).

Results

Data from 20,511 cases were analyzed. The overall prevalence of laboratory-
50 confirmed influenza in the study sample was 38.8% ($n = 7,955$). Table 1 summarizes the estimates. The prevalence of laboratory-positive influenza was lower among elder subjects, particularly during the COVID-19 pandemic period (65+ years old, 13.2%). The mean sensitivity of case definition was high in all age groups and the last general estimate (92.7, 95% CI 91.3-94.1) was similar to the
55 previous ones $p = 0.274$.

The overall specificity computed during the pandemic period was 12.2%(95% CI 10.5-14.0) and it was higher than the estimate from Period 3 ($p = 0.001$) but lower than the estimate from March-April 2019 ($p < 0.001$). The diagnostic

accuracy went from 48.7% to 38.0% (22% decrease; $p < 0.001$) in Period 3 and
60 4, respectively; it was the similar to the accuracy from Period 1 ($p = 0.459$).

The AUROCs are presented in Figure 1 and ranged from 0.544 (95% CI 0.533-0.556) to 0.607 (95% CI 0.586-0.628). No significant differences were documented between the pre- and during-pandemic periods ($p = 0.855$).

Discussion

65 This study evaluated the performance of influenza case definition based on a national and normative influenza cohort. Our results suggest no significant changes in the evaluated parameters before and during the COVID-19 pandemic. The analyzed cohort study has several strengths and include: (i) influenza virus infection was confirmed by qRT-PCR analysis, which is the gold standard; (ii)
70 the database included cases from all age groups and (iii) data of influenza A and B viruses was available.

Timely identification of influenza virus infection can assist healthcare providers in determining optimal strategies for preventing or treating influenza, including the use of antiviral drugs. These interventions also reduce the spread of
75 influenza [11].

Multiple suspected influenza case definitions are currently being used worldwide and include, among others, the proposed by CDC [11], WHO [12], and the *GROG* [13]. All of them have a similar performance in detecting laboratory-positive cases and their sensitivity and specificity ranges from 90 to 96%, and
80 from 7 to 21%, respectively [5]. The computed AUROCs by using any of these classifications are similar to those that were estimated in our study (≈ 0.550).

No differences in the performance of the case definition or symptoms in influenza cases according to virus type were found in a recently published study [14]. The identified influenza virus sub-types were as following ($n = 7,955$):
85 A/H1N1, 57%; B/Victoria, 17%; A/H3, 16%; B/Yamagata, 9% and B unidentified, 1%.

Seasonal influenza vaccination has been proven to be cost-effective in the

prevention of seasonal influenza [15], however low acceptance rates have been documented among Mexicans, even in high-risk groups (elderly, about 56%)
90 [16]. Vaccination coverage among persons of productive age is even lower (20%) [17].

Conclusions

Our findings suggest that the suspected case definition employed in community surveillance of influenza has a good performance, even during the COVID-
95 19 pandemic. Therefore, this definition may be used in identifying patients who may benefit from early access to neuraminidase inhibitors. Timely use of antiviral drugs, together with immunization promoting, may reduce the social and economic burden of influenza.

References

- 100 [1] L. P. Newman, N. Bhat, J. A. Fleming, K. M. Neuzil, Global influenza seasonality to inform country-level vaccine programs: an analysis of who flunet influenza surveillance data between 2011 and 2016, *PloS one* 13 (2) (2018). doi:10.1371/journal.pone.0193263.
- [2] N. Jones, How coronavirus lockdowns stopped flu in its tracks, Accessed on May 24, 2020. doi:0.1038/d41586-020-01538-8.
105 URL <https://www.nature.com/articles/d41586-020-01538-8>
- [3] Dirección General de Epidemiología de México, Manual para la vigilancia epidemiológica de Influenza, Accessed on May 26, 2020.
URL [https://www.gob.mx/salud/documentos/](https://www.gob.mx/salud/documentos/manuales-para-la-vigilancia-epidemiologica-102563)
110 [manuales-para-la-vigilancia-epidemiologica-102563](https://www.gob.mx/salud/documentos/manuales-para-la-vigilancia-epidemiologica-102563)
- [4] A. Influenza, Modified surveillance of influenza a (h1n1) v virus infections in france, *Eurosurveillance* 14 (29) (2009) 19276. doi:10.2807/ese.14.29.19276-en.
- [5] J.-S. Casalegno, D. Eibach, M. Valette, V. Enouf, I. Daviaud, S. Behillil,
115 A. Vabret, J. C. Soulyar, M. Benchaib, J. M. Cohen, et al., Performance of influenza case definitions for influenza community surveillance: based on the french influenza surveillance network grog, 2009-2014, *Eurosurveillance* 22 (14) (2017). doi:10.2807/1560-7917.ES.2017.22.14.30504.
- [6] Secretaría de Salud de México, Comunicado Técnico Diario Nuevo Coronavirus en el Mundo (COVID-19): 28 de febrero de 2020, Accessed on May
120 27, 2020.
URL https://www.gob.mx/cms/uploads/attachment/file/538453/Comunicado_Tecnico_Diario_COVID-19_2020.02.28.pdf
- [7] Secretaría de Salud de México, COVID-19: Información general, Accessed
125 on May 27, 2020.
URL <https://coronavirus.gob.mx/datos/>

- [8] World Health Organization and others, Q&a: Similarities and differences—
covid-19 and influenza, Website: <https://www.paho.org/hq/index.php>
Accessed on May 24, 2020 (2020).
- 130 [9] C. J. Heneghan, I. Onakpoya, M. A. Jones, P. Doshi, C. B. Del Mar,
R. Hama, M. J. Thompson, E. A. Spencer, K. R. Mahtani, D. Nunan,
et al., Neuraminidase inhibitors for influenza: a systematic review and
meta-analysis of regulatory and mortality data., *Health Technology As-*
essment 20 (42) (2016). doi:10.3310/hta20420.
- 135 [10] L. Fernandes-Matano, I. Monroy-Muñoz, M. B. de León, Y. Leal-Herrera,
I. Palomec-Nava, J. Ruíz-Pacheco, B. Escobedo-Guajardo, C. Marín-Budip,
C. Santacruz-Tinoco, J. González-Ibarra, et al., Analysis of influenza
data generated by four epidemiological surveillance laboratories in mex-
ico, 2010–2016, *Epidemiology & Infection* 147 (2019). doi:10.1017/
S0950268819000694.
140
- [11] S. Hariri, E. Dunne, M. Saraiya, E. R. Unger, L. E. Markowitz, *Manual
for the surveillance of vaccine-preventable diseases*. chapter 6: Influenza
(2011).
- [12] World Health Organization and others, *Who surveillance case definitions
for ili and sari*, Geneva: WHO. January
145 Accessed on May 24, 2020 (2014).
- [13] J. Aguilera, W. Paget, A. Mosnier, M. Heijnen, H. Uphoff, J. Van der
Velden, T. Vega, J. Watson, Heterogeneous case definitions used for the
surveillance of influenza in europe, *European journal of epidemiology* 18 (8)
(2003) 751–754. doi:10.1023/a:1025337616327.
- 150 [14] À. Domínguez, N. Soldevila, N. Torner, A. Martínez, P. Godoy, C. Rius,
M. Jané, et al., Usefulness of clinical definitions of influenza for public
health surveillance purposes, *Viruses* 12 (1) (2020) 95. doi:10.3390/
v12010095.

- [15] K.-C. Yang, H.-F. Hung, M.-K. Chen, S. L.-S. Chen, J. C.-Y. Fann, S. Y.-
155 H. Chiu, A. M.-F. Yen, K.-C. Huang, H.-H. Chen, S.-T. Wang, Cost-effectiveness analysis of universal influenza vaccination: Application of the susceptible–infectious–complication–recovery model, *International Journal of Infectious Diseases* 73 (2018) 102–108. doi:10.1016/j.ijid.2018.05.024.
- 160 [16] B. Trejo-Valdivia, L. R. Mendoza-Alvarado, O. Palma-Coca, M. Hernández-Ávila, M. M. T.-R. Solís, Encuesta nacional de cobertura de vacunación (influenza, neumococo y tétanos) en adultos mayores de 60 años en México, *salud pública de México* 54 (1) (2012) 39–46.
- [17] I. H. Ejebe, X. Zhang, M. G. Rangel, A. P. Martinez-Donate, Seasonal influenza vaccination among Mexican migrants traveling through the Mexico–
165 US border region, *Preventive medicine* 71 (2015) 57–60. doi:10.1016/j.ypmed.2014.12.004.

Tables and Figures

Table 1. Performance of suspected influenza case definition, Mexico 2018-2020

Age	n	Prevalence	Estimate (95% Confidence Interval)			LR+	LR-
			Sensitivity	Specificity	Accuracy		
Period 1 (October 2018 - February 2019)							
5-9	626	59.3	91.1 (88.9-93.3)	16.5 (13.6-19.4)	60.7 (56.9-64.5)	1.091	0.540
10-19	539	49.5	92.1 (89.9-94.4)	12.9 (10.0-15.7)	52.1 (47.9-56.3)	1.057	0.611
20-44	4,159	38.6	94.1 (93.4-94.8)	8.6 (7.8-9.5)	41.6 (40.1-43.1)	1.029	0.688
45-64	2,806	33.8	91.1 (90.1-92.2)	9.5 (8.4-10.6)	37.1 (35.3-38.8)	1.007	0.932
65+	2,001	15.9	87.4 (86.0-88.9)	14.8 (13.2-16.4)	26.3 (24.4-28.3)	1.026	0.850
All	10,131	34.6	92.2 (91.7-92.7)	10.9 (10.3-11.5)	39.1 (38.1-40.0)	1.035	0.713
Period 2 (March 2019 - April 2019)							
5-9	214	65.4	92.9 (89.4-96.3)	13.5 (8.9-18.1)	65.4 (59.1-71.8)	1.074	0.529
10-19	224	63.0	93.6 (90.4-96.8)	10.8 (6.8-14.9)	63.0 (56.6-69.3)	1.050	0.589
20-44	841	40.8	96.8 (95.6-98.0)	9.4 (7.5-11.4)	45.1 (41.7-48.4)	1.069	0.340
45-64	515	28.2	93.8 (91.7-95.9)	8.7 (6.2-11.1)	32.6 (28.6-36.7)	1.027	0.718
65+	440	15.0	86.4 (83.2-89.6)	11.2 (8.3-14.2)	22.5 (18.6-26.4)	0.973	1.214
All	2,234	37.4	91.4 (90.2-92.5)	17.6 (16.1-19.2)	41.2 (39.2-43.4)	1.109	0.490
Period 3 (October 2019 - February 2020)							
5-9	489	65.0	89.3 (86.6-92.0)	13.5 (10.4-16.5)	62.8 (58.5-67.1)	1.032	0.795

Table 1 continued from previous page
 Table 1. Performance of suspected influenza case definition, Mexico 2018-2020

Age	n	Prevalence	Estimate (95% Confidence Interval)				LR+	LR-
			Sensitivity	Specificity	Accuracy			
10-19	519	61.5	91.9 (89.5-94.2)	8.5 (6.1-10.9)	59.7 (55.5-63.9)	1.004	0.959	
20-44	3,044	53.9	95.1 (94.4-95.9)	7.1 (6.2-8.0)	54.6 (52.8-56.3)	1.024	0.690	
45-64	1,666	38.9	93.7 (92.5-94.8)	10.0 (8.6-11.5)	42.6 (40.2-44.9)	1.041	0.632	
65+	1,094	24.0	90.5 (88.7-92.2)	11.5 (9.6-13.4)	30.4 (27.7-33.2)	1.023	0.827	
All	6,812	46.8	93.5 (93.0-94.1)	9.3 (8.6-10.0)	48.7 (47.6-49.9)	1.031	0.695	
<i>Period 4 (March 2020 - April 2020)</i>								
5-9	79	63.3	94.0 (88.8-99.2)	20.7 (11.8-29.6)	67.1 (56.7-77.4)	1.185	0.290	
10-19	81	50.6	95.1 (90.4-99.8)	15.0 (7.2-22.8)	55.6 (44.7-66.4)	1.119	0.325	
20-44	736	34.9	92.2 (90.3-94.2)	10.7 (8.4-12.9)	39.1 (35.6-42.7)	1.032	0.731	
45-64	249	21.7	92.6 (89.3-95.8)	11.3 (7.4-15.2)	28.9 (23.3-34.5)	1.044	0.657	
65+	189	13.2	92.0 (88.1-95.9)	15.9 (10.6-21.1)	25.9 (19.7-32.2)	1.093	0.505	
All	1,334	32.0	92.7 (91.3-94.1)	12.2 (10.5-14.0)	38.0 (35.4-40.6)	1.057	0.593	

Abbreviations: **LR**, likelihood ratio.




Figure 1: Area Under the Receiver Operating Characteristics (AUROC) and 95% Confidence intervals (CI) of suspected influenza case definition, Mexico 2018-2020

Note: No significant differences were documented between the pre- (a-c) and during-pandemic (d) periods ($p = 0.855$).